Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,798.00+1.29%ETH$2,290.84+1.67%GOLD$3,940.20-0.01%OIL$96.76+0.70%
Smart Investors Daily
SID Premium
VE

NASDAQ · VERA

Vera Therapeutics, Inc.

Healthcare · Biotechnology

$30.25

Up+$0.46 (+1.52%)

Updated Nov 3, 2026, 11:01 PM

SID Score

4.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.94B
P/E ratio
-13.44
Dividend yield
0.00%
52-week range
$26.38 – $47.00
Volume
2.11M
Avg. volume
1.59M

Price performance · VERA

VERA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

VERA closed at $30.25 after 21 trading sessions, up 1.41% for the selected period.

Last close
$30.25
Period change
+1.41%
Period low
$26.74
Period high
$31.20
Daily close
View OHLC price history
VERA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$31.05$32.78$30.23$30.252.11M
Oct 30, 2026$30.30$31.29$29.56$30.981.08M
Oct 29, 2026$31.32$31.905$30.36$30.531.11M
Oct 28, 2026$29.77$31.13$29.77$30.941.28M
Oct 27, 2026$28.35$30.02$28.21$29.991.07M
Oct 26, 2026$27.94$28.53$27.56$28.301.17M
Oct 23, 2026$28.75$29.44$27.46$27.991.98M
Oct 22, 2026$30.99$31.84$28.71$29.052.55M
Oct 21, 2026$30.01$31.565$29.85$31.202.08M
Oct 20, 2026$28.92$30.52$28.87$30.061.19M
Oct 19, 2026$28.20$29.24$27.61$28.921.27M
Oct 16, 2026$28.30$28.40$27.50$27.881.29M
Oct 15, 2026$27.28$28.825$27.13$28.571.53M
Oct 14, 2026$26.845$27.42$26.375$26.741.53M
Oct 13, 2026$27.62$27.73$26.5501$26.792.99M
Oct 12, 2026$29.11$29.4925$27.64$27.721.41M
Oct 9, 2026$29.57$30.51$29.46$29.88996.58K
Oct 8, 2026$30.00$30.25$28.74$29.731.73M
Oct 7, 2026$29.09$30.61$28.46$30.253.29M
Oct 6, 2026$29.98$30.1024$28.37$29.422.4M
Oct 5, 2026$30.58$30.735$28.79$29.832.72M

Latest VERA news

The latest Smart Investors Daily articles mentioning VERA.

Stock researchCompany · Overview

VERA research

Overview

Company profile and research snapshot.

Company profile

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.25
Implied upside
—
Analysts
—
VERA recent ratings
DateFirmRatingTarget
Oct 12, 2026Leerink PartnersMarket Perform—
Sep 8, 2026JP MorganOverweight—
Aug 17, 2026WedbushNeutral—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 11, 2026WedbushNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 2, 2026

Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, which is taking place in Boston, MA from November 9-11, 2026. The management team will also participate in one-on-one investor meetings. Fireside Chat Details:Date: Tuesday, November 10, 2026Time: 11:30 AM ETWebcast:

Yahoo · Oct 23, 2026

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology’s Kidney Week meeting in Denver, alongside publication in T

Yahoo · Oct 22, 2026

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.Favorable safety profile, and generally comparable to placebo. Plan to submit supplemental BLA to the U.S. FDA in Q4 2026 for full approval expected in 2027.Investor webcast is scheduled for October 22 at 4:30 pm EDT. BRISBANE, Calif., Oct. 22

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By